Literature DB >> 29438841

Anti-migraine and anti-depression activities of Tianshu capsule by mediating Monoamine oxidase.

Xiaoping Sun1, Fangfang Zhu1, Jun Zhou1, Xiujuan Chang1, Liang Li1, Hanfei Hu1, Zhenzhong Wang1, Wei Xiao2.   

Abstract

BACKGROUND: Tianshu capsule(TSC)is a Chinese patent medicine. It's widely used to treat migraine clinically in China. AIM OF THE STUDY: In the present study, we investigated anti-migraine and anti-depression activities of TSC using in vivo animal models together with in vitro studies to investigate the mechanism of action.
MATERIALS AND METHODS: Nitroglycerin (NTG) -induced migraine rat model, rat was given a subcutaneous injection of the NTG suspension (10 mg/kg) once a week for 5 weeks. Behavioral observation was carried out and brain tissues were sampled to determine levels of 5-hydroxytryptamine (5-HT), dopamine (DA), norepinephrine (NE), monoamine oxidase A (MAO-A), monoamine oxidase B (MAO-B) and tyrosine hydroxylase (TH) by ELISA, in order to evaluate the effect of TSC on migraine progression. Tail suspension test and forced swim test were carried in order to evaluate the effect of TSC on depression progression.
RESULTS: TSC treatments decreased scratch head times significantly in a rat migraine model. Meanwhile, TSC suppressed activities of MAO-A and MAO-B, up-regulated 5-HT, DA and NE expressions in brain tissues. Tail suspension test showed a decrease of immobility time in TSC groups. Furthermore, TSC increased climb times, up-regulated activities of 5-HT, DA and NE in forced swim test mice. Additionally, TSC could attenuate the reduction of 5-HT, DA and NE induced by corticosterone in primary neuronal cells.
CONCLUSION: TSC could effectively prevent depression, one of the most frequent comorbidities in migraine. It may provide a new target for treating migraine.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Depression; Migraine; Monoamine oxidase; Primary neuronal cells; Tianshu capsule

Mesh:

Substances:

Year:  2018        PMID: 29438841     DOI: 10.1016/j.biopha.2018.01.171

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  2 in total

1.  Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial.

Authors:  Shengyuan Yu; Ye Ran; Wei Xiao; Wenjing Tang; Jianjun Zhao; Wei Chen; Huikui Zhuang; Cun Ouyang; Hai Lin; Dequan Liu; Tongjun Chen; Hui Huang; Baoshen Wang; Yanlei Hao; Zhongrui Yan; Shike Zhao; Yanling Wang; Jinjun Ni; Chaodong Wang; Wentao Ding; Guoqian Li; Jianhua Cao; Shujuan Tian
Journal:  BMC Complement Altern Med       Date:  2019-12-16       Impact factor: 3.659

2.  Auricular Electrical Stimulation Alleviates Headache through CGRP/COX-2/TRPV1/TRPA1 Signaling Pathways in a Nitroglycerin-Induced Migraine Rat Model.

Authors:  Chung-Chih Liao; Jung-Miao Li; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-11       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.